StreetInsider.com News Articles

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Brege Laura

Wed, 17 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660932.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Brege Laura

Wed, 17 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660932.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Thompson Peter A.

Wed, 17 Jun 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260617/26660700.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Thompson Peter A.

Wed, 17 Jun 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260617/26660700.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Morris Arlene

Wed, 17 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260617/26660675.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Morris Arlene

Wed, 17 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260617/26660675.html

Edgewise Therapeutics (EWTX) PT Raised to $59; RBC Capital: 'We would be buyers on weakness'

Wed, 17 Jun 2026 07:43:43 -0400

(Updated - June 17, 2026 7:43 AM EDT)

RBC Capital analyst Leonid Timashev raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $59.00 (from $48.00) while maintaining an Outperform rating.

The analyst commented: "Stock Reaction Was 'Heart Pounding', But Data Should Reassure That '7500 Could Be Best In Disease; Today EWTX reported 12 week results from their HCM trial for '7500 and we had a chance to catch up with mgmt. We think that today's data delivered on both compelling safety and efficacy, with the potential to allow the company to design a ph.III without titration echos and ultimately deliver on

Edgewise Therapeutics (EWTX) PT Raised to $59; RBC Capital: 'We would be buyers on weakness'

Wed, 17 Jun 2026 07:43:43 -0400

(Updated - June 17, 2026 7:43 AM EDT)

RBC Capital analyst Leonid Timashev raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $59.00 (from $48.00) while maintaining an Outperform rating.

Edgewise Therapeutics (EWTX) PT Raised to $59; RBC Capital: 'We would be buyers on weakness'

Wed, 17 Jun 2026 07:43:43 -0400

(Updated - June 17, 2026 7:43 AM EDT)

RBC Capital analyst Leonid Timashev raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $59.00 (from $48.00) while maintaining an Outperform rating.

Edgewise Therapeutics (EWTX) PT Raised to $32 at Goldman Sachs

Wed, 17 Jun 2026 05:30:06 -0400

Goldman Sachs analyst Paul Choi raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $32.00 while maintaining a Neutral rating.

The analyst comments "Phase 2 EDG-7500 data showcase functional improvements in both oHCM and nHCM; near-term focus on Phase 3 specifics with the long-term debate on whether the HCM treatment paradigm can decouple from echo scans. EWTX shares are volatile intraday (range: -12% to +5%, currently -5% vs. XBI: flat), which we think reflects the generally positive but also mixed 12-weeks Part D results from the open label, Phase 2 CIRRUS-HCM study of EDG-7500 in oHCM and nHCM. While we

Edgewise Therapeutics (EWTX) PT Raised to $32 at Goldman Sachs

Wed, 17 Jun 2026 05:30:06 -0400

Goldman Sachs analyst Paul Choi raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $32.00 while maintaining a Neutral rating.

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Edris Badreddin

Tue, 16 Jun 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260616/26655556.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Edris Badreddin

Tue, 16 Jun 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260616/26655556.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Martin Christopher Nathan

Tue, 16 Jun 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260616/26655553.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Martin Christopher Nathan

Tue, 16 Jun 2026 18:17:00 -0400

si-local-file:///var/storage/secattach/20260616/26655553.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Fox Jonathan C

Tue, 16 Jun 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26655548.html

Form 4 Edgewise Therapeutics, For: Jun 05 Filed by: Fox Jonathan C

Tue, 16 Jun 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26655548.html

Edgewise Therapeutics (EWTX) PT Raised to $52 at Leerink

Tue, 16 Jun 2026 13:08:40 -0400

Leerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a Outperform rating.

The analyst comments "We continue to think that CIRRUS Part D checks the key boxes for EDG-7500 across obstructive (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM) and safety, and we come away with increased confidence in Phase 3 success. We recognize the key investor pushbacks are the new onset cases of atrial fibrillation (AF), apparent KCCQ “regression” versus the prior nHCM readout, and skepticism that EDG-7500 can avoid echo-based monitoring. However, we think the Part D dataset largely addresses these

Edgewise Therapeutics (EWTX) PT Raised to $52 at Leerink

Tue, 16 Jun 2026 13:08:40 -0400

Leerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a Outperform rating.

Edgewise Therapeutics (EWTX) PT Raised to $52 at Leerink

Tue, 16 Jun 2026 13:08:40 -0400

Leerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a Outperform rating.

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events.